ANAB · AnaptysBio, Inc.

Current Thesis

AnaptysBio’s thesis is that the Jemperli litigation restores product rights to the company; a written judgment granting reversion would establish that outcome, while a weekly close below $52 would invalidate the published market case first. The court calendar establishes procedural milestones, not the probability of success. The 2026-07-30 company disclosure sets defendants’ answering brief for 2026-09-25, AnaptysBio’s reply for 2026-10-09 and post-trial argument for 2026-10-20. Company disclosure reproduced by StockTitan.

The September conference has now supplied substantive updates. On 2026-09-15, CFO Chris Murphy said the opening brief was filed on 2026-08-21 and confirmed that the court has set no judgment date. He attributed an expected fourth-quarter or following-first-quarter decision window to GSK; that is an expectation, not a court deadline. Conference transcript.

The life-cycle assessment remains an inference: the narrative is maturing — the timetable disclosed on 2026-07-30 remained operative at the 2026-09-15 conference, while the supplied adjusted market record shows an 8.0% three-month decline through 2026-09-18. These observations establish an unresolved, established story; they do not establish expanding participation or the likely legal outcome.

Bullish and bearish views on AnaptysBio, Inc.

The model's bull view on AnaptysBio, Inc. (ANAB), in brief: The royalty asset is growing. At the 2026-09-15 conference, Murphy cited GSK’s first-half 2026 Jemperli global net sales of $644 million, up 34% year over year. This is management’s account of GSK sales, not AnaptysBio’s June-quarter royalty receipt. Conference transcript.… The bear view: Authorisation has not become demand. Murphy said on 2026-09-15 that the company’s $100 million repurchase programme had not been used. Its existence therefore supplies no evidence of completed corporate purchases supporting the shares. Conference transcript. The June-quarter… Both cases follow in full.

Bull Case

• The royalty asset is growing. At the 2026-09-15 conference, Murphy cited GSK’s first-half 2026 Jemperli global net sales of $644 million, up 34% year over year. This is management’s account of GSK sales, not AnaptysBio’s June-quarter royalty receipt. Conference transcript.
• Reported royalties provide an operating anchor. AnaptysBio’s 2026-05-12 results disclosed first-quarter Jemperli royalties of $24.7 million, up 44% year over year, within collaboration revenue of $25.6 million. Those historical results establish a revenue-producing asset independently of the requested legal remedy. First-quarter results.
• April preserved the existing economics. The 2026-04-24 Chancery ruling, reported in the supplied Benzinga coverage, dismissed Tesaro’s anticipatory-breach claim and rejected its royalty-reduction request. That ruling supports the existing royalty contract; it does not establish that AnaptysBio will obtain product reversion.

Bear Case

• Authorisation has not become demand. Murphy said on 2026-09-15 that the company’s $100 million repurchase programme had not been used. Its existence therefore supplies no evidence of completed corporate purchases supporting the shares. Conference transcript.
• The June-quarter disclosure remains unverified. The investor overview reviewed on 2026-09-20 still displayed the 2026-05-12 first-quarter release as its latest financial-results announcement. No June-quarter royalty figure was established by the reviewed material. This is a verification gap, not evidence of a filing violation or accounting failure. Company investor overview.
• Argument does not schedule judgment. The 2026-07-30 disclosure specifies argument on 2026-10-20 but supplies no opinion date. The calendar alone cannot support a forecast that the reversion question resolves inside the next month. Company disclosure reproduced by StockTitan.

Setup & Price Structure

The supplied split- and dividend-adjusted record gives a 2026-09-18 close of $55.20, 20.9% below the recorded 52-week high of $69.81, with an 8.0% decline over three months. The 14-period relative strength index, a momentum measure, was 44.8 on that date. These measurements do not confirm an accelerating price trend.

The $52 weekly-close threshold remains the research invalidation published on 2026-09-06. The available adjusted record does not independently establish that number as a repeatedly tested support shelf, so it should not be described as one. A breach would invalidate the market thesis without proving that the court had ruled adversely.

Crowding is unmeasured. The 2026-09-15 conference documents public coverage, but neither that appearance nor the supplied 2026-09-18 momentum reading measures retail concentration. A comparable short-interest series, moving-average distance and verified insider transaction details are absent from the reviewed evidence; no crowded-trade conclusion follows.

Catalyst Calendar (next 30 days)

The window runs from 2026-09-20 through 2026-10-20. The following dates come from the company’s 2026-07-30 disclosure of the court-approved schedule. Post-trial schedule.

• 2026-09-25 — Defendants’ answering brief. The scheduled submission provides the defendants’ post-trial response; filing it is not a decision on the merits.
• 2026-10-09 — AnaptysBio’s reply brief. This is the scheduled company response before argument, not a ruling date.
• 2026-10-20 — Post-trial oral argument. This is the final scheduled step identified in that disclosure before a decision; the written opinion remains undated.

As reviewed on 2026-09-20, the company events page lists the 2026-09-15 conference among past events and lists no upcoming events. No company-confirmed earnings date is established by that page. Company events calendar.

What Would Change Our Mind

Failure of the published price condition would end the market case: a weekly close below $52 is the explicit invalidation, retained from the 2026-09-06 research record. Separately, a written judgment denying the requested product reversion would defeat the legal thesis even if the market threshold had not yet failed.

The positive resolution is equally specific: a written judgment granting reversion before that price breach would establish the thesis outcome. An answering brief or the arrival of the 2026-10-20 argument date would not suffice. The low-conviction assessment reflects the absence of evidence supporting a legal-success probability and the declining three-month price record through 2026-09-18; procedural progress alone does not justify stronger odds.

Correlation Notes

This remains a single-name setup: the supplied 2026-09-20 coverage context assigns no active theme cluster to ANAB. No return-correlation study is available, so no numerical relationship with biotechnology indices or other litigation situations is asserted.

The economic link to GSK is direct. At the 2026-09-15 conference, Murphy said Jemperli royalties and milestones currently flow directly to Sagard until the monetisation obligation is satisfied. Product sales therefore inform the asset’s economics, but they are not interchangeable with cash available to AnaptysBio. Conference transcript.